ClinicalTrials.gg
Not yet recruitingNCT06077110Updated Mar 28, 2025

Precision Care Initiative: Integrating Precision Oncology Into Clinical Programs

An interventional study of Precision Care Clinic services in Cancer, sponsored by The University of New South Wales. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by The University of New South Wales · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to drive integration of precision medicine into routine oncology healthcare. It is hoped that this research will not only optimise the newly established Precision Care Clinic within the Prince of Wales Hospital, but also prime it for use within other health care sites. The multidisciplinary team will work to achieve the following three objectives:

  1. Co-design a Precision Care Clinic, its implementation platform and suite of outcome measures (Phase 1)
  2. Test the implementation-, service-, clinical, and cost-effectiveness of a Precision Care Clinic (Phase 2)
  3. Develop and pilot test a Precision Care scale-up model and toolkit (Phase 3)

A mixed-methods approach will be used to develop and evaluate an implementation platform to support the integration of precision medicine into the routine oncology setting at a single hospital site. In the first study phase, interviews and focus-groups will be used to develop the implementation platform, which involves a co-designed model of care supported by a Learning Health System. A Type II Hybrid effectiveness-implementation trial design will then be used to test the implementation, clinical, and cost-effectiveness of this novel model of care (phase 2). A combination of patient surveys and interviews will be used to measure patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs); stakeholder and patient interviews, surveys and focus-groups will be used to measure implementation outcomes; and cost data will be collected to inform an economic evaluation. These data will be collected at various stages of implementation to evaluate the effectiveness of the model of care over time. In the final study phase (phase 3), a scale-up model will be developed to support implementation of the new model of care across a wider range of clinical contexts. (Phase 3 will be detailed in a separate ethics amendment)

It is hoped that this research will not only optimise the newly established model of care within The Prince of Wales Hospital, but also prime it for use within other health care sites.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • precision medicine
  • oncology
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 300 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

The University of New South Wales is the lead sponsor of 66 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have been referred to the Precision Care Clinic at POWH
  • speak English
  • are aged 18 years or over
  • are able to provide

Exclusion criteria

Exclusion Criteria:

  • aged under 18 years
  • non-English speaking
  • are unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Precision Care Clinic patients

    Other: Precision Care Clinic services

Interventions

  • OtherPrecision Care Clinic services

    The Service Intervention is the Precision Care Clinic being delivered at the Prince of Wales Hospital. This clinic provides a streamlined, multidisciplinary model to seamlessly integrate research-led precision medicine into the routine oncology setting.

06

What researchers measure

Primary outcomes

  1. Implementation Outcomes

    appropriateness (e.g., perceived fit); qualitative measurement collected via interviews/focus groups/questionnaires

    Time frame: 3 months post-referral

  2. Implementation Outcomes

    acceptability (clinician satisfaction); qualitative measurement collected via interviews/focus groups/questionnaires

    Time frame: 3 months post-referral

  3. Implementation Outcomes

    feasibility; qualitative measurement collected via interviews/focus groups/questionnaires

    Time frame: 3 months post-referral

  4. Implementation Outcomes

    adoption (e.g., telehealth uptake); qualitative measurement collected via interviews/focus groups/questionnaires

    Time frame: 3 months post-referral

  5. Implementation Outcomes

    fidelity (care model adopted as intended); qualitative measurement collected via interviews/focus groups/questionnaires

    Time frame: 3 months post-referral

  6. Implementation Outcomes

    cost (e.g., immediate versus ongoing implementation resource); qualitative measurement collected via interviews/focus groups/questionnaires

    Time frame: 3 months post-referral

  7. Implementation Outcomes

    penetration (e.g., research enrolment numbers including culturally and linguistically diverse, remote/regional); qualitative measurement collected via interviews/focus groups/questionnaires

    Time frame: 3 months post-referral

  8. Implementation Outcomes

    sustainability \[industry engagement, grant support; clinical trial \& access options, research links (e.g., sub-studies) generated\]; qualitative measurement collected via interviews/focus groups/questionnaires

    Time frame: 3 months post-referral

  9. Service Outcomes

    Upstream indicators of clinical effectiveness: intervals between time from referral to treatment; captured via audit data; measured in days; a smaller value indicates a preferred outcome.

    Time frame: 3 months post-referral

  10. Service Outcomes

    Upstream indicators of clinical effectiveness that include: uptake of precision oncology treatment recommendations; captured via audit data; measured in percentages; a higher value indicates a preferred outcome.

    Time frame: 3 months post-referral

  11. Service Outcomes

    Upstream indicators of clinical effectiveness that include: time from identification of germline research result to familial cancer clinic referral; captured via audit data, measured in days; a smaller value indicates a preferred outcome.

    Time frame: 3 months post-referral

  12. Service Outcomes

    Upstream indicators of clinical effectiveness that include: time from identification of germline research result to clinical confirmation; captured via audit data, measured in days; a smaller value indicates a preferred outcome.

    Time frame: 3 months post-referral

  13. Clinical Outcomes

    Patient reported experience of coordinated care; collected via questionnaires adapted for the precision medicine context; measured as ratings; a higher rating indicates a preferred outcome.

    Time frame: 3 months post-referral

Secondary outcomes

  1. Clinical Outcome: Quality of life improvement (EQ-5D-5L, EuroQol-5 Dimension-5 Level)

    Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). There are 3,125 possible health states defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health).

    Time frame: 3, 6, 9 months post-referral

  2. Clinical Outcome: Views and attitudes (patient-perceived benefits and drawbacks of process and care model), result return preferences, knowledge, perceived importance of genomic profiling

    qualitative measures captured via interviews/questionnaires

    Time frame: 3, 6, 9 months post-referral

  3. Clinical Outcome: Psychological outcomes (e.g., anxiety and depression, coping with uncertainty)

    qualitative measures captured via interviews/questionnaires

    Time frame: 3, 6, 9 months post-referral

  4. Clinical Outcome: Decisional outcomes (e.g., decisional regret regarding personalised treatment, decisional satisfaction)

    qualitative measures captured via interviews/questionnaires

    Time frame: 3, 6, 9 months post-referral

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Jan 2027, 20 months later.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 20 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Oct 11, 2023
StartEst.
May 2025
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06077110
Lead sponsor
The University of New South Wales
Responsible party
Natalie Taylor (Associate Professor, The University of New South Wales) — Principal investigator
First posted
Oct 11, 2023
Start date
May 2025 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Mar 28, 2025

Study contacts

Shuang Liang, PhD
Contact
shuang.liang4@unsw.edu.au
+61 2 9348 1126
Natalie Taylor, PhD
Contact
natalie.taylor@unsw.edu.au
+61 2 9348 1126
Natalie Taylor, PhD
principal investigator · The University New South Wales

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion